Litcius/Paper detail

Should resection extent be decided by total lesion size or solid component size in ground glass opacity-containing lung adenocarcinomas?

Boyu Lin, Rui Wang, Liang Chen, Zhitao Gu, Chunyu Ji, Wentao Fang

2021Translational Lung Cancer Research26 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Indication for sublobar resections in early-stage lung adenocarcinomas has been controversial. The purpose of this study was to find appropriate selection criteria for sublobar resections in ground glass opacity (GGO)-containing early-stage lung adenocarcinomas. METHODS: We retrospectively studied 985 consecutive patients with clinical stage IA, peripheral GGO-containing lung adenocarcinomas ≤3 cm in size. According to their radiological appearance, they were divided into a pure GGO group and a part-solid nodule (PSN) group. The PSN group was further divided into a GGO-predominant subgroup and a solid-predominant subgroup. Propensity-score matching (PSM) was conducted first in PSNs with similar total lesion size and then in those with similar solid component size to eliminate potential confounders. Histological characteristics and prognosis were compared between matched patients to investigate the prognostic value of total lesion size and solid component size. Then solid component size was chosen as the selection criterion to compare the prognosis of patients receiving lobectomy or sublobar resections. RESULTS: 90.0%, P=0.893). CONCLUSIONS: Solid component size better predicts histological characteristics and prognosis than total lesion size in early-stage GGO-containing lung adenocarcinomas. Instead of total lesion size, solid component size ≤2 cm may be a more appropriate selection criterion for sublobar resections in such patients.

Topics & Concepts

Ground-glass opacityMedicineLesionLungLung cancerAdenocarcinomaStage (stratigraphy)RadiologyNodule (geology)Subgroup analysisNuclear medicinePathologyInternal medicineCancerConfidence intervalBiologyPaleontologyLung Cancer Diagnosis and TreatmentHepatocellular Carcinoma Treatment and PrognosisLung Cancer Treatments and Mutations